107篇中国论文涉嫌造假 遭国外期刊撤稿

Tumor Biology, a Springer journal, retracted 107 articles in a single notice last Thursday.

在上周四的一则通知中，斯普林格出版社旗下的期刊《肿瘤生物学》宣布撤销107篇论文。

The supposedly peer-reviewed papers did not appropriately go through the peer-review process, the publisher and editor of the paper writes in a terse note accompanying the list of discredited studies.

论文出版社以及编辑用简洁的口吻写道，本应经过同行评议的这些论文，并没有正规地完成这一流程。随附的还有疑似论文的名单。

"After a thorough investigation we have strong reason to believe that the peer review process was compromised," they write.

他们写道：“在全面调查后，我们有足够的理由相信同行评议是造假的。”

The papers are predominantly authored by scientists from China, and were published from 2012 up until last year. The subjects span from the impacts of smoking on cancer, to gene-specific effects on tumors.

这些论文的作者主要是来自中国的科学家，发表时间为2012年至去年。论文主题涵盖了抽烟对于癌症的影响、基因特异性对于肿瘤的影响。

The site Sixth Tone first reported on the massive retraction. One of Springer's editorial directors told the Chinese media outlet that the studies had been submitted with suggestions from reviewers with real names – but with fabricated email addresses.

《第六声》网站首先报道了此次大规模撤稿事件。斯普林格出版社的一名编辑主任向中国的媒体透露，这些论文提交时附有实名评议员的意见，但是电子邮件地址是伪造的。

Springer is not the first major publisher to discover widespread peer review problems prompting mass retractions.

斯普林格并非是第一家通过发现大范围同行评议问题从而引起大规模撤稿的重要出版社。

BioMed Central retracted 43 papers in one action in November 2014, and Hindawi Publishing Corporation announced in 2015 that three editors had "subverted" the entire editorial process in publishing 32 papers.

2014年11月，BioMed Central出版社曾一次性撤销过43篇论文；另外，Hindawi出版社于2015年宣布，三名编辑“破坏了”32篇论文发布的整个编辑过程。